A specialty medical devices company that is developing products for treatment of oral inflammation and acute and chronic wounds based on our chemical formulations that act as aggressive desiccation and debriding agents. We refer to this proprietary process as Desiccation Shock Technology (“DST”). Eleven published clinical trials have shown that our products reduce and, very often, eliminate the need for antibiotics to treat topical infectious wounds, including oral infections and open infectious wounds. Standard treatments can take months and even years of daily antibiotic use to heal an open infectious wound. In 2021, our HYBENX and ERADX product lines received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”), as a medical device for use as an adjunctive rinse of tooth root surfaces during periodontal debridement procedures, including scaling and root planing, to aid in the removal of contaminated debris from the sulcus.
